ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

milvexian

Also written as “BMS-986177”, “Milvexian” and “JNJ-70033093”.

Its studies are mostly in Thrombosis · Ischemic Stroke · Atrial Fibrillation · Acute Coronary Syndrome · Stroke, led by 2 companies.

Drug pageMilvexian: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 20, 201625 company-led studies, 2 open or runningCo-development: Bristol Myers Squibb and Janssen (Johnson & Johnson), Apr 2018Next primary completion: Dec 8, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb140 open or runningphase 2since Dec 20, 2016Nov 17, 2015none ahead
Johnson & Johnsonits history only112 open or runningphase 3since Jan 19, 2023Mar 25, 2019Dec 8, 2026phase 3 · NCT05757869
  • Named in Bristol-Myers Squibb’s own pipeline as milvexian, phase 3, as of Oct 29, 2026 (source).
  • Named in Johnson & Johnson’s own pipeline as milvexian, phase 3, as of Oct 13, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 17, 2015First study: phase 1 study in ThrombosisFirst studyNCT02608970 · 104 enrolled · Belgium
  2. Jun 17, 2016Phase 1 study in ThrombosisNCT02807909 · 28 enrolled
  3. Aug 24, 2016Phase 1 study in ThrombosisNCT02902679 · 6 enrolled · United States
  4. Nov 7, 20162 phase 1 studies in ThrombosisNCT02959060, NCT02982707
  5. Dec 20, 2016Phase 2 study in AntithromboticNCT03000673 · 32 enrolled · United States
  6. Jun 21, 2017Phase 1 study in ThrombosisNCT03196206 · 24 enrolled · United States
  7. Jul 18, 2017Phase 1 study in ThrombosisNCT03224260 · 33 enrolled · United States
  8. Oct 30, 2017Phase 1 study in StrokeNCT03341390 · 20 enrolled · United States
  9. Nov 30, 2017Phase 1 study in ThrombosisNCT03362437 · 12 enrolled · United Kingdom
  10. Apr 16, 2018Janssen (Johnson & Johnson) develops it with Bristol Myers SquibbCo-developmentWorldwide, development costs and profits shared · announced · Johnson & Johnson
  11. Oct 4, 2018Phase 1 study in Healthy VolunteersNCT03698513 · 113 enrolled · United States
  12. Nov 13, 2018Phase 2 study in Ischemic StrokeNCT03766581 · 2,366 enrolled · United States, Argentina, Australia and more
  13. May 2, 2019Phase 1 study in ThrombosisNCT03939702 · 9 enrolled · United States
  14. Jun 9, 2020Named milvexianINNProposed as its International Nonproprietary Name in WHO's List 123 · before, BMS-986177, JNJ-70033093
  15. Jul 7, 2021Phase 1 study in Healthy VolunteersNCT04965389 · 17 enrolled · United Kingdom

TargetBeta

“A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation”study text, read by Claude · the study

Other programs on F11

ProgramCompanyFurthest phaseStudies
abelacimabanthos-therapeutics-incphase 38
SHR-2004Jiangsu HengRui Medicinephase 35

Studies

All 14 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04965389Healthy Volunteers · United Kingdom1CompletedAug 22, 202117
NCT03939702Thrombosis · United States1CompletedJul 11, 20199
NCT03766581Ischemic Stroke · United States, Argentina, Australia and more2CompletedMar 31, 20222,366
NCT03698513Healthy Volunteers · United States1CompletedFeb 19, 2019113
NCT03362437Thrombosis · United Kingdom1CompletedDec 28, 201712
NCT03341390Stroke · United States1CompletedNov 16, 201720
NCT03224260Thrombosis · United States1CompletedNov 7, 201733
NCT03196206Thrombosis · United States1CompletedMar 4, 201824
NCT03000673Antithrombotic · United States2CompletedOct 23, 201732
NCT02982707Thrombosis · United States1CompletedSep 28, 201826
NCT02959060Thrombosis1CompletedDec 201616
NCT02902679Thrombosis · United States1CompletedJun 20176
NCT02807909Thrombosis1CompletedAug 201628
NCT02608970Thrombosis · Belgium1CompletedJul 23, 2017104

How it is read

Names in the registry

  • “BMS-986177”, 14 entries
  • “Milvexian”, 6 entries
  • “JNJ-70033093”, 4 entries
  • “JNJ-70033093 25 mg”, 1 entry
  • “JNJ-70033093 50 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.